Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire

Julia Walter1,2,4*, Laura Sellmer1,2†, Kathrin Kahnert1,2, Rosemarie Kiefl1, Zulfiya Syunyaeva1, Diego Kauffmann-Guerrero1,2, Farkhad Manapov2,3, Christian Schneider2,4, Juergen Behr1,2 and Amanda Tufman1,2

Abstract

Background: The novel coronavirus SARS-CoV-2 has caused a global COVID-19 pandemic, leading to worldwide changes in public health measures. In addition to changes in the public sector (lockdowns, contact restrictions), hospitals modified care to minimize risk of infection and to mobilize resources for COVID-19 patients. Our study aimed to assess the impact of these measures on access to care and behaviour of patients with thoracic malignancies.

Methods: Thoracic oncology patients were surveyed in October 2020 using paper-based questionnaires to assess access to ambulatory care services and tumor-directed therapy during the COVID-19 pandemic. Additionally, behaviour regarding social distancing and wearing of face masks were assessed, as well as COVID-19 exposure, testing and vaccination. Results are presented as absolute and relative frequencies for categorical variables and means with standard deviation for numerical variables. We used t-test, and ANOVA to compare differences in metric variables and Chi²-test to compare proportions between groups.

Results: 93 of 245 (38%) patients surveyed completed the questionnaire. Respiration therapy and physical therapy were unavailable for 57% to 70% of patients during March/April. Appointments for tumor-directed therapy, tumor imaging, and follow-up care were postponed or cancelled for 18.9%, 13.6%, and 14.8% of patients, respectively. Patients reported their general health as mostly unaffected. The majority of patients surveyed did not report reducing their contacts with family. The majority reduced contact with friends. Most patients wore community masks, although a significant proportion reported respiratory difficulties during prolonged mask-wearing. 74 patients (80%) reported willingness to be vaccinated against SARS-CoV-2.

Conclusions: This survey provides insights into the patient experience during the second wave of the COVID-19 pandemic in Munich, Germany. Most patients reported no negative changes to cancer treatments or general health; however, allied health services were greatly impacted. Patients reported gaps in social distancing, but were prepared...
Background
The novel coronavirus SARS-CoV-2 has caused a global COVID-19 pandemic, leading to worldwide changes in public health measures. In addition to changes in the public sector (lockdowns, contact restrictions), hospitals modified care to minimize risk of infection and to mobilize resources for COVID-19 patients. Patients with thoracic malignancies may be particularly affected by public health measures. On the one hand these patients may be at risk of severe COVID complications due to advanced age and comorbidities [1, 2]. On the other hand, patients with thoracic tumors, particularly with locally advanced or metastatic disease, are in need of regular therapy and follow-up care including tumor imaging. The European Society for Medical Oncology (ESMO) was quick to implement new guidelines to help caretakers adjust and prioritize outpatient and inpatient visits for therapy, imaging and follow-up care for cancer patients [3]. They allocated high priority for visits for the continuation of in- and outpatient therapies like intravenous chemotherapy and immune therapy as well as radiotherapy, and imaging for patients at a high risk for relapse and to confirm a cancer diagnosis [3]. Follow-up visits for patients with a low or intermediate risk for relapse after radical therapy were allocated a lower priority [3]. Where possible, teleconsulting was recommended. These recommendations resulted in a conversion of in person visits to phone or video consultations in 52% of patients with contacts to a hospital in March and April 2020 according to a study from The Netherlands [4]. Other studies report substantial decreases in cancer screening and diagnosis as well as treatment [5, 6]. In a global survey of oncology care centers, 36.5% of the respondents reported exposure to harm for patients due to interruption of cancer-specific care and 39.0% reported harms due to interruption of non-cancer related care. 46.3% of centers indicated that more than 10% of their patients missed at least one cycle of chemotherapy [7]. So far, there are no studies measuring gaps in care due to the pandemic in Germany, specifically Bavaria, which was one of the most affected regions during the first wave. Therefore, the aim of our study was to (1) assess the amount of disruption in ambulatory and cancer-related care, (2) assess subjective effects on patients’ health; and (3) assess patient compliance with social distancing guidelines and community masks as well as willingness to be vaccinated in patients with thoracic malignancies.

Methods
Study design, patient cohort and data collection
In this cross-sectional study we assessed the experience of thoracic oncology patients during the COVID-19 pandemic concerning access to healthcare, effects on their health, and COVID-19 exposure.

We considered all patients whose cases had been reviewed in the multidisciplinary thoracic oncology tumor board of the thoracic oncology center Munich during the last 3 years, excluding those who had been surveyed as part of our longitudinal telephone-based COVID-19 survey [8]. In addition, we excluded patients treated primarily at other centers (e.g. patients who consulted us for second opinions, patients presented to the tumor board by external physicians, and patients with a documented change of health care provider), patients with metastatic disease who had not had contact with our center during the previous 6 months, and lastly patients who were presented to the board with pulmonary diseases other than lung cancer.

We sent out paper-based questionnaires, patient information, and consent forms to the identified patients. Patients had one month to complete the questionnaire. The questionnaire and the signed consent form were then sent back in a pre-paid envelope. Additional medical history details (histology, stage, current state of disease, current therapy, and comorbidities) were obtained from electronic patient records. Charlson comorbidity score was calculated from ICD codes found in the electronic patient records [9–11]. The primary thoracic oncology diagnosis was not included as a comorbidity for calculation of the Charlson comorbidity index (CCI).

Ethics
Approval for this cross-sectional non-interventional study was obtained from the Ethics Committee of the Ludwig-Maximilians University. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local ethical and legal requirements.

Questionnaire
The questionnaire was designed by our study team (including an epidemiologist, a biologist, and a thoracic oncology specialist). It was designed to evaluate the impact of the COVID-19 pandemic on access to ambulatory care, out- and inpatient tumor-directed care,
behavior and effects on subjective general health during the COVID-19 pandemic, and questions directly related to COVID-19. In the first block of questions we asked about availability of physical therapy, respiration therapy, self-help groups, and medical sports courses during the height of the pandemic (March/April 2020). In the second block we asked about appointments for tumor imaging, out- and inpatient intravenous therapy (chemotherapy or immunotherapy), radiotherapy, tumor surgeries, and follow-up visits during oral therapy (tyrosine kinase inhibitors) and after other tumor-directed therapies, previously scheduled for March and April 2020. The third block of the questionnaire consisted of questions regarding social distancing behavior in private life (meeting family and friends) and relating to doctor visits (visits to primary care physicians (GP), and pneumologists/oncologist or other specialists), effects of the pandemic on patients’ subjective general health and mask wearing habits and difficulties in mask wearing. These questions were asked on a 5 level Likert scale ranging from strong agreement to strong disagreement. The fourth question block directly related to COVID-19 exposure, polymerase chain reaction (PCR) and antibody testing, as well as the willingness to get vaccinated. Patient demographics included age, gender, education, working status, and household size For validation purposes, the questionnaire was reviewed by a thoracic oncology physician as well as an external public health expert, and tested on several internal and external test subjects.

Statistical analysis
All data were pseudonymized prior to analysis. We reported descriptive statistics as absolute and relative frequencies for categorical and ordinal variables and as mean with standard deviation for all metric variables. Metric variables were tested for normal distribution using Shapiro–Wilk-Test. As the chance of the Shapiro–Wilk-Test to be statistically significant with increasing n [12], we additionally performed graphical inspection of the histogram and the QQ-Plot. Respondents and non-respondents were compared using, Students t-test for age and Chi²-test, for gender, histology and stage. We performed tests of association with the degree of agreement and age, CCI, gender, metastases status, and education level for the ten questions of question block number three (social distancing and behavior). We used analysis of variance (ANOVA) test for age and CCI, and Chi²-test for gender, metastases status, and education level. We applied a threshold of \( \alpha < 0.05 \) for significance in all analyses.

Data analysis was performed using R Version 4.0.0. Tables and figures were created in Microsoft Excel.

Results

Patient population and demographics
Of the 1036 cases discussed in the tumor board of our center during the past 3 years, 790 were excluded due to the exclusion criteria for this study. The patient flow diagram in Fig. 1 shows the reasons for exclusion of patients. Of the remaining 246 patients receiving the questionnaire, 93 (38%) completed the questionnaire and gave consent to be included in this study.

Mean patient age was 66.7 years and 60.2% of patients were male. Information on level of education, working status, histology, stage at diagnosis, current disease status and therapy, as well as comorbidity are displayed in Table 1. Characteristics of respondents were comparable to non-respondents concerning age, gender, histology and stage. Almost all variables were distributed equally in respondents and non-respondents (see Table 2).

Availability of ambulatory care

14 (15.1%) patients attended ambulatory respiration therapy before the start of the COVID-19 pandemic. For 8 (57.1%) patients this service was unavailable during the height of the pandemic, for one patient it was still unavailable at the time of the study, 20 patients (21.5%) received physical therapy at the beginning of the pandemic, which was unavailable in March and April due to the pandemic for 14 (70%) and available again for 9 patients (45%) at the time of the study. 5 (5.4%) patients participated in a medical sports group and 2 (2.2%) in a self-help group. Both of these services were unavailable in March and April, but available again at the time of completing the questionnaire.

Inpatient and ambulatory tumor therapy
37 patients (39.8%) had an appointment scheduled for either surgery, chemotherapy, immunotherapy or radiotherapy during March or April. Of these, 7 (18.9%) indicated that this appointment was cancelled (n = 1) or moved to a different date (n = 6) due to the pandemic. The number of days an appointment had been moved was available for three patients and ranged from 3 to 7 days. One patient with stage I had their surgery date moved to a later date, the other 5 patients had stage II or IV disease and indicated their appointments for intravenous therapy or radiotherapy had been moved.

Of the 44 (47.3%) patients with a scheduled appointment for tumor imaging (CT, MRI, PET-CT), 6 (13.6%) had this appointment moved (n = 5) or cancelled (n = 1). The number of days the appointments had been moved was longer compared to tumor therapy and ranged between 5 and 180 days. Four of these patients had stage I or II and were scheduled for follow-up care after curative therapy.
Follow-up care appointments (after surgery or during oral therapy, radiotherapy, chemotherapy or immunotherapy) were planned for 54 (58.1%) patients, and moved (n = 7) or cancelled (n = 1) for 8 (14.8%) of those. If provided, the number of days ranged between 7 and 45 days. This group included mostly patients with follow-up care after curative therapy and patients treated with oral tyrosine kinase inhibitors (TKIs).

**Patient health and behavior**

Patients were asked to describe changes to their interpersonal contacts due to COVID-19. More patients indicated limiting contact to friends and acquaintances (48.6%) rather than limiting contact to family members (23.2%). 15.4% of patients said they avoided visits to their primary care physician due to COVID-19, a smaller proportion (5.4%) avoided visits to their pneumologist, oncologist or other specialist. Age, CCI, gender, metastases status were not significantly associated with different levels of agreement. Education level was significantly associated with the statement about meeting family members as well as with visiting their GP, however there was no clear trend in any direction.

The majority of patients did not feel like their general health was affected by the pandemic due to changes in access to medical care (91.4%) or due to the stay-at-home orders (87.1%). Patients who indicated effects on their general health due to restricted access to healthcare or...
public restrictions were generally younger; however, this difference did not yield significance. Both statements were also not significantly associated with gender, metastatic disease status, education, and CCI.

45.1% of patients indicated that they wore a face mask even in places where it was not mandatory. This was significantly associated with gender (p-value = 0.04), with females being more open to wearing it. However, only 59.8% of patients were confident that they are physically able to wear a face mask over extended periods of time. Around a quarter of all patients felt they experienced shortness of breath or anxiety while wearing a face mask. Age, CCI, metastatic disease status, and education level were not significantly associated with mask wearing behavior.

Figures 2, 3 and 4 display proportions for all questions with 5 level Likert scale. Additional file 1: Table S1 and Additional file 2: Table S2 display associations with age and CCI, and with gender, metastases status, and education level, respectively.

COVID-19 exposure, testing, and vaccination
2 patients reported having been in close contact (RKI class I contact) with a person that was infected with COVID-19 at that time. 52 (55.9%) said they had been tested for COVID-19 with a PCR test since the beginning of the pandemic, 9 (9.7%) patients were tested for SARS Cov-2 antibodies. No patients tested positive for COVID-19 or antibodies. The majority of patients (79.6%) said they would agree to get vaccinated against COVID-19. Reasons for not getting vaccinated included fear or insecurity about side effects of the vaccine (4 patients), and fear that the vaccine was developed too quickly (8 patients). 2 patients were still undecided about getting vaccinated. Patients open to getting vaccinated were older (67.7 vs. 63.4) than those unwilling to get vaccinated or those who were not sure yet, however this difference was not significant.

Discussion
Several surveys regarding experiences of cancer care providers during the pandemic have been published. We believe that this study of patient reported experiences complements and completes the picture presented by the provider perspective. Using paper-based questionnaires, we were able to assess difficulties in access to care as well as exposure to infection and testing of patients with thoracic malignancies (mostly lung cancer) due to the COVID-19 pandemic in Bavaria, Germany. Overall, we found that although some patients (between 13 and 19%) had their appointments cancelled or moved to a different date, the majority of patients received their tumor-directed therapies, tumor imaging, and follow-up care as planned. However, allied health services (e.g. physical therapy, respiratory therapy) were affected to a greater extent and mostly (57–100%) unavailable during the phase of the complete lockdown in March and April. These aspects of care have only slowly started to become available again. Social distancing was not implemented
strictly by the majority of patients, with only 49% of patients reporting avoiding meetings with friends and only 23% avoiding seeing family members by the time of the study in October 2020. Only a small proportion of patients (< 10%) said they were avoiding doctor visits, the proportion who did was higher when asked about their GP compared to their pneumologist/oncologist or other specialist. Younger patients more often felt a negative effect of the pandemic on their subjective general health; however, this difference was not significant. Moreover, the majority of patients did not report experiencing negative effects on their general health. The willingness to get vaccinated against SARS-CoV-2 was high (around 80%) and reasons given did not indicate strict refusal but rather insecurity.

A study measuring gaps in cancer treatment due to the COVID-19 pandemic in cancer patients from the Netherlands found that between 12 to 16% of patients experienced postponement of treatments. This finding was similar in our study where 19% of patients reported postponement or cancellation of scheduled appointments for treatments like radiotherapy, chemotherapy, immunotherapy or surgery. Another global study among 54 countries found that 46.3% of oncology centers reported that more than 10% of their patients missed at least one cycle of chemotherapy [7]. When an appointment for tumor therapy was moved, we found that it was moved by a week at the maximum. Therefore, we believe these changes were due to organizational aspects rather than due to the pandemic. The delay in appointments for imaging were greater, reaching 180 days at the maximum. Affected patients were mostly in lower stages, so the risk of recurrence was considered negligible compared to the risk of infection with COVID-19. These findings are in line with ESMO guidelines which allocated high priority for visits for the continuation of in- and outpatient therapies like intravenous chemotherapy and immune therapy as well as radiotherapy, and imaging for patients at a high risk for relapse and to confirm a cancer diagnosis [3]. Lower priority was assigned to follow-up visits for patients with a low or intermediate risk for relapse after radical therapy [3]. The ESMO guidelines also

### Table 2 Comparison of respondents and non-respondents

|                      | Respondents (n = 93) | Non-respondents (n = 153) | p-value       |
|----------------------|----------------------|---------------------------|---------------|
|                      | Mean     sd          | Mean     sd          |               |
| Mean age (sd)        | 66.9 10.4 | 67.7 12.3 | 0.71<sup>a</sup> |
| Female               | 40 43.0 | 67 43.8 | 1.00<sup>b</sup> |
| Male                 | 53 57.0 | 86 56.2 |               |
| Histology            |           |             |               |
| Adenocarcinoma       | 51 54.8 | 77 50.3 | 0.58<sup>b</sup> |
| Squamous-cell carcinoma | 16 17.2 | 29 19.0 | 0.86<sup>b</sup> |
| SCLC                 | 4 4.3   | 6 3.9   | 1.00<sup>c</sup> |
| Mediastinal tumor    | 3 3.2   | 9 5.9   | 0.54<sup>c</sup> |
| Other                | 16 17.2 | 20 13.1 | 0.48<sup>b</sup> |
| Unknown              | 3 3.2   | 12 7.8  | 0.23<sup>c</sup> |
| Stage at diagnosis   |           |             |               |
| I                    | 26 28.0 | 43 28.1 | 1.00<sup>b</sup> |
| II                   | 12 12.9 | 17 11.1 | 0.82<sup>b</sup> |
| III                  | 26 28.0 | 32 20.9 | 0.45<sup>b</sup> |
| IV                   | 25 26.9 | 41 26.8 | 0.66<sup>b</sup> |
| Unknown              | 4 4.3   | 20 13.1 | 0.02<sup>c</sup> |

Comparison of patient characteristics of respondents and non-respondents as means with standard deviation for numeric and relative and absolute frequencies of categorical variables. P-values from Chi² and Fisher-Exact Test (n in cell < 6) for categorical and from T-Test for numerical variables.

<sup>a</sup> T-test  
<sup>b</sup> Chi²-Test  
<sup>c</sup> Fisher-Exact Test
encouraged teleconsultations wherever possible, which seems to be reflected in care, with one survey of 109 representatives from oncology centers reporting that at the peak of the pandemic oncologists used teleconsultations to replace follow-up appointments (94.5%), to monitor oral therapy (92.7%), and to monitor patients receiving immunotherapy (57.8%) or chemotherapy (55%) [13].

Other aspects of allied health care may be more difficult to provide via telemedicine. Exercise such as physical therapy and respiration therapy have been shown to benefit patients with cancer even in advanced stages, increasing control of treatment-related symptoms such as fatigue, and improving patients quality of life [14]. In our study the majority of patients attending such programs reported that these services were not available during the height of the pandemic and were only slowly becoming available again. Newton et al. have published practical recommendations for keeping patients with cancer exercising during the pandemic, including video-communication and in-home exercise [15].

A survey across several European countries measured the willingness to get vaccinated against COVID-19 in more than 7500 people. They found an overall willingness in 74% of respondents, the willingness in Germany was 70% [16]. According to the Germany COVID-19 Snapshot Monitoring (COSMO Germany) the willingness to get vaccinated in the German population has declined from around 79% in April to 50% in October 2020 [17]. In our survey respondents, the willingness to get vaccinated was higher (80%) than the general German population. This higher proportion may reflect thoracic oncology patient perceptions of their individual risk for complications from COVID-19. Additionally, older patients were more likely to indicate a willingness to get vaccinated. Advanced age as well as having a cancer diagnosis are risk factors for complications from COVID-19 [1, 2].

The survey reported here was conducted in a single lung cancer center in Bavaria, Germany. While the results offer a snapshot of the patient experience in
Munich, experiences during the pandemic are likely to vary regionally and may also vary between centers in a region. The survey was intended to capture a broad range of patient experiences and was, therefore, mailed out to patients with all types of primary thoracic malignancy and all stages of disease. It included patients with NSCLC, SCLC, mesothelioma and thymus tumors, with patients currently undergoing treatment as well as patients under surveillance and follow-up care. However, as not all surveys were returned, the results may include an element of bias based on patients’ willingness to participate in the survey. However, we did not find that respondents and non-respondents were significantly different regarding age, gender, histology, and stage. However, the definition of our study exclusion criteria may have introduced a selection bias to patients included and excluded for the study. As lung cancer has a median survival time of less than a year and we looked at tumor board records from the previous three years, a higher proportion of patients with lower stage at diagnosis were left to include after excluding deceased patients and patients who were likely deceased. As can be seen in Fig. 1, the majority of patients excluded were patients with metastatic disease who did not visit our center during the 6 months prior to the begin of our study. We expected that these patients most probably were deceased, and we did not want to risk addressing questionnaires to grieving family members. Additionally, as our questionnaire was mailed out only in the German language, there might be an underrepresentation of patients with non-German first language. Nevertheless, apart from stage, basic demographic parameters suggest that the survey respondents were similar to the average lung cancer patient. Mean age of the respondents was 66.7 years which is close to the mean age at diagnosis of German lung cancer patients (male: 69.3, female: 68.3) [18]. The proportion of male patients in our study (60%) was comparable to the proportion of male patients among newly diagnosed patients in Germany in 2016 which was 65% [18].

This is the first study to measure specific consequences of the COVID-19 pandemic on ambulatory services as well as in- and outpatient visits from the perspective of thoracic oncology patients in Germany, and, to our knowledge, internationally. Additionally, the study evaluated effects on patient health and patient’s behavior, views and feelings towards social distancing, mask wearing and vaccination. While several studies have reported the physician perspective and described changes to the provision of care, the patient perspective is particularly valuable in demonstrating the effects of those changes, as well as compliance with distancing and lock-down recommendations. In many respects, our results are reassuring and show that, while the pandemic has forced some changes in care, the majority of patients were able to receive most aspects of care as planned and have coped well with the changes that occurred. Other results, such as the relatively high proportion of patients who report not having limited social or family contacts, imply a need for further public health education measures aimed at specific patient groups. Alternatives to mask-wearing should be investigated for those patients who experience respiratory difficulties during extended periods of community mask use.

**Conclusion**

This survey of patient experiences demonstrates that the subjective impact of the COVID-19 pandemic on tumor-directed care and general patient health for thoracic oncology patients was minimal. Access to some ambulatory allied health services was greatly reduced. Many patients did not reduce social or family contacts. Most patients wore masks, although many patients reported respiratory symptoms during mask-wearing. The willingness to get vaccinated against SARS-CoV-2 was high. This information is of high relevance to both policy makers and healthcare providers.
Abbreviations
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Corona virus disease 2019; ESMO: European Society of Medical Oncology; ICD: International classification of disease; CCI: Charlson comorbidity index; GP: General physician; PCR: Polymerase chain reaction; LCSS: Lung cancer symptom scale; NSCLC: Non-small-cell-lung-cancer; COSMO: COVID-19 snapshot monitoring; SCLC: Small-cell-lung-cancer; RKI: Robert Koch Institut.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-022-01931-z.

Additional file 1: Table S1. Supplemental material: Comparison of age and CCI according to degree of agreement.

Additional file 2: Table S2. Supplemental material: Comparison of gender, metastatic disease status and education level according to degree of agreement.

Acknowledgements
Not applicable.

Authors’ contributions
AT was responsible for conceptualization, methodology, resources, and writing of the original draft. KK, ZS, DK, FM, CS, JB were involved in writing and editing the manuscript. RK was conducting involved in data curation. LS and JW designed the questionnaire, analyzed the data and were involved in writing and editing the original manuscript. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This research received funding from Takeda Pharma Vertrieb GmbH & Co. KG.

Availability of data and materials
The datasets used and analysed during this current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
Approval for this prospective non-interventional study was obtained from the Ethics Committee of the Ludwig-Maximilians University. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local ethical and legal requirements. Questionnaires, patient information and consent to participation forms were mailed out. Only questionnaires accompanied by a signed consent form were used for analysis in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Internal Medicine V, Thoracic Oncology Centre Munich, Ludwig-Maximilians University Munich (LMU), Ziemssenstraße 1, 80336 Munich, Germany. 2 German Center for Lung Research (DZL CPC-M), Aulweg 130, 35392 Giessen, Germany. 3 Department of Radiation Oncology, Thoracic Oncology Centre Munich, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany. 4 Department of Thoracic Surgery, Thoracic Oncology Centre Munich, Ludwig-Maximilians University Munich, Marchioninistrasse 15, 81377 Munich, Germany.

Received: 17 February 2021  Accepted: 10 January 2022
Published online: 29 January 2022

References
1. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
3. Lung cancer in the COVID-19 era. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era.
4. de Joode K, Dumoulin DW, Engelen V, Bloemendal HJ, Verheij M, van Lung Cancer in the COVID-19 era. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era. 2020;395(10229):1054–62.
5. Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, Markward N, Sullivan M, Peng J, Zhou A. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Informat. 2020;4:1059–71.
6. Greenwood E, Swanton C. Consequences of COVID-19 for cancer care—an CRUK perspective. Nat Rev Clin Oncol. 2020;18:3–4.
7. Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razs ED, Mula-Hussain L, Ennabi H, Khattak A, De Guzman RB, et al. Impact of the COVID-19 pandemic on cancer care: a global collaborative study. JCO Glob Oncol. 2020;6:1428–38.
8. Walter J, Sellmer L, Kahrert K, Zauber R, Syunyaeva Z, Kauffmann-Guerrero D, Manapov F, Schneider C, Behr J, Tufman A. Daily routine and access to care: initial patient reported experiences at a german lung cancer center during the COVID-19 pandemic. Respiration. 2020;100:90–2.
9. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
11. Field AP. Discovering statistics using IBM SPSS statistics. SAGE Publications; 2018.
12. Jerusalem G, Onesti CE, Generali DG, Harbeck N, Wildiers H, Curigliano G, Campone M, Tjan-Heijnen V, Martin M, Cristofanilli M, et al. LBA76_PR expected medium and long term impact of the COVID-19 outbreak in oncology. Ann Oncol. 2020;31:S205–6.
13. Ottius KL, Gramling RE, Ades PA. Exercise interventions for individuals with advanced cancer: a systematic review. Prev Med. 2017;104:124–32.
14. Newton RU, Hart NH, Clay T. Keeping patients with cancer exercising in the age of COVID-19. JCO Oncol Pract. 2020;16(10):656–64.
15. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyogg J, Stargar T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020;21(7):977–82.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

17. Impfungen. https://projekte.uni-erfurt.de/cosmo2020/web/topic/impfung-10-impfungen/#was-denken-persoenen-%C3%B6ber-verschiedene-impfstofftypen.
18. Zentrum für Krebsregisterdaten im Robert Koch-Institut: Bericht zum Krebsgeschehen in Deutschland 2016. In: Berlin; 2016.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions